Publications by authors named "R A Villasenor"

Recent advancements in engineering Complex models (CIVMs) such as Blood-brain barrier (BBB) organoids offer promising platforms for preclinical drug testing. However, their application in drug development, and especially for the regulatory purposes of toxicity assessment, requires robust and reproducible techniques. Here, we developed an adapted set of orthogonal image-based tissue methods including hematoxylin and eosin staining (HE), immunohistochemistry (IHC), multiplex immunofluorescence (mIF), and Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI-MSI) to validate CIVMs for drug toxicity assessments.

View Article and Find Full Text PDF
Article Synopsis
  • Parque Nacional La Campana (PNLC) is famous for its diverse plant and animal life, but this study focused on examining the lesser-known microbial communities present in its ecosystems.
  • Researchers analyzed soil samples from different plant types found in PNLC, like sclerophyllous and xerophytic forests, using advanced DNA sequencing techniques to identify microbial composition.
  • The study revealed specific microbial communities linked to various plant ecosystems, highlighting that factors like elevation and soil type significantly influence the diversity and structure of microbes in the park.
View Article and Find Full Text PDF
Article Synopsis
  • Scientists found that special marks on DNA can control how genes are turned on and off.
  • They made a new method called Chrom-seq to find RNA that works with these DNA marks in living cells.
  • This new method is better, faster, and cheaper than older ways and doesn’t need special antibodies to study RNA linked to DNA marks that might help control gene activity.
View Article and Find Full Text PDF

Mutations in glucocerebrosidase cause the lysosomal storage disorder Gaucher's disease and are the most common risk factor for Parkinson's disease. Therapies to restore the enzyme's function in the brain hold great promise for treating the neurological implications. Thus, we developed blood-brain barrier penetrant therapeutic molecules by fusing transferrin receptor-binding moieties to β-glucocerebrosidase (referred to as GCase-BS).

View Article and Find Full Text PDF